High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: The French experience

International Journal of Cancer

Volumn 83, Issue 6, 1999, Pages 844-847

  Flechon A ^a   Biron, P ^b   Droz, J P ^b  

^a CENTRE LÉON BÉRARD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FRANCE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SEMINOMA; SURVIVAL RATE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032730753     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991210)83:6<844::AID-IJC28>3.0.CO;2-6     Document Type: Conference Paper

References (25)

1. BEYER, J. and 12 OTHERS, High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. clin. Oncol., 14, 2638-2645 (1996).
2. BIRCH, R., WILLIAMS, S.D., CONE, A., EINHORN, L.P., ROARK, P., TURNER, S. and GRECO, F.A., Prognostic factors for favorable outcome in disseminated germ cell tumors. J. clin. Oncol., 4, 400-407 (1986).
3. BIRON, P., BRUNAT-MENTIGNY, M., BAYLE, J.Y., CLAVEL, M., GUASTALLA, J.P., BOUFFET, E., CHAUVIN, F. and PHILIP, T., Cisplatinum-VP 16 and ifosfamide (VIC) + autologous bone marrow transplantation in poor prognostic non-seminomatous germ cell tumors. Proc. Amer. Soc. clin. Oncol., 8, 148 (1989).
4. BIRON, P., PHILIP, T. and MARANINCHI, D., Massive chemotherapy and autologous bone marrow transplantation in progressive disease of non-seminomatous testicular cancer: a phase II study on 15 patients. In: K.A. Dicke, G. Spitzer and A.R. Zander (eds.), Autologous bone marrow transplantation, pp. 203-210, University of Texas, Houston (1985).
5. CHEVREAU, C., DROZ, J.P., PICO, J.L., BIRON, P., KERBRAT, P., CURE, H., HÉRON, J.F., CHEVALLIER, B., FARGEOT, P., KRAMAR, A. and BOUZY, J., No evidence of a benefit of early intensified chemotherapy (HDCT) with autologous bone marrow transplantation (ABMT) in first-line treatment of poor-risk non-seminomatous germ cell tumours (NSGCT). Europ. Urol., 23, 213-218 (1993).
6. CULINE, S. and 12 OTHERS ON BEHALF OF THE GENITO-URINARY GROUP (GETUG) OF THE FRENCH FEDERATION OF CANCER CENTERS, Are 3 cycles of bleomycin, etoposide, and cisplatin (3 BEP) or 4 cycles of etoposide and cisplatin (4 EP) equivalent regimens for patients with good risk metastatic non-seminomatous germ cell tumors? Preliminary results of a randomized trial. Proc. Amer. Soc. clin. Oncol., 18, 390a. Abstract 1188 (1999).
7. DROZ, J.P. and 13 OTHERS, Prognostic factors in advanced non-seminomatous testicular cancer. A multivariate logistic regression analysis. Cancer, 62, 564-568 (1988).
8. DROZ, J.P., KRAMAR, A. and PICO, J.L., Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Europ. J. Cancer, 29A, 818-821 (1993).
9. DROZ, J.P., PICO, J.L. and GHOSN, M., High-dose chemotherapy with autologous bone marrow transplantation in non-seminomatous germ cell tumors. New Drugs New Regimens, 2, 228-244 (1992).
10. DROZ, J.P., PICO, J.L., GHOSN, M., GOUYETTE, A., BAUME, D., PIOT, G., OSTRONOFF, M., THÉODORE, C., BEAUJEAN, F. and HAYAT, M., Long-term survivors after salvage high-dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Europ. J. Cancer, 27, 831-835 (1991).
11. DROZ, J.P., PICO, J.L., GHOSN, M., KRAMAR, A., REY, A., OSTRONOFF, M. and BAUME, D., A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non-seminomatous germ cell tumors. Bull. Cancer (Paris), 79, 497-507 (1992).
12. FARHAT, F., CULINE, S., THÉODORE, C., BEKRADDA, M., TTERRIER-LACOMBE, M.J. and DROZ, J.P., Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumors patients: the Institut Gustave Roussy experience. Cancer, 77, 1193-1197 (1996).
13. FLÉCHON, A., BIRON, P., PHILIP, I., BLAY, J.Y. and DROZ, J.P., High-dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the Centre Léon Bérard between 1982 and 1996. Bull Cancer (Paris), 86, 391-399 (1999).
14. IBRAHIM, A., ZAMBON, E., BOURHIS, J.H., OSTRONOFF, M., BEAUJAN, F., VIENS, P., LHOMMÉ, C., CHAZARD, M., MARANINCHI, D., HAYAT, M., DROZ, J.P. and PICO, J.L., High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Europ. J. Cancer, 29A, 1398-1403 (1993).
15. INTERNATIONAL GERM CELL CANCER COLLABORATIVE GROUP, International germ cell consensus classification, a prognostic factor-based staging system for metastatic germ cell cancers. J. clin. Oncol., 16, 1244-1247, (1998).
16. LOEHRER, P.J., GONIN, R., NICHOLS, C.R., WEATHERS, T. and EINHORN, L.H., Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumors. J. clin. Oncol., 16, 2500-2504 (1998).
17. MILLER, A.B., HOOGSTRATEN, B. and STAQUET, M., Reporting results of cancer treatment. Cancer, 47, 207-214 (1987).
18. MOTZER, R.J., GULATI, S.C., TONG, W.P., MENENDEZ-BOTET, C., LYN, P., MAZUMDAR, M., VLAMIS, V., LIN, S. and BOSL, G.J., Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res., 53, 3730-3755 (1993).
19. NICHOLS, C.R. and 13 OTHERS, Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. clin. Oncol., 7, 932-939 (1989).
20. NICHOLS, C.R., WILLIAMS, S., LOEHRER, P.J., GRECO, F.A., CRAWFORD, D.E., WEETLAUFER, J., MILLER, M.E., BARTOLUCCI, A., SCHACTER, L. and EINHORN, L.H., Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. clin. Oncol., 9, 1163-1172 (1991).
21. OZOLS, R.F., CORDEN, B.J. and JACOB, J., High-dose cisplatin in hypertonic saline. Ann. Intern. Med., 100, 19-24 (1984).
22. OZOLS, R.F., IHDE, D.C., LINEHAN, W.M., JACOB, J., OSTCHEGA, Y. and YOUNG, R.C., A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis non-seminomatous germ cell tumors. J. clin. Oncol., 6, 1031-1040, (1988).
23. PICO, J.L., IBRAHIM, A., CASTAGNA, L., BOURHIS, J.H., CHAZARD, M., MARANINCHI, D. and DROZ, J.P., Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology, 50 (Suppl. 2), 47-52 (1993).
24. SAXMAN, S.B., FINCH, D., GONIN, R. and EINHORN, L.H., Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ cell tumors: the Indiana University experience. J. clin. Oncol., 16, 702-706 (1998).
25. WILLIAMS, S.D., BIRCH, R., EINHORN, L.H., IRWIN, L.., GRECO, F.A. and LOEHRER, P.J., Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435-1440, (1987).